A rare but common problem
With increasing competition from genetics and payors pushing back on drug prices, manufacturers have tacked away from the old blockbuster model – developing lifestyle and primary care drugs that could be used in a large population – and invested in novel therapies for rare diseases. But the space is increasingly crowded. When the model first started, treating rare disease was, well, rare. Today, it’s common, writes Michelle Hoffmann, senior vice president of strategy consulting at Boston-based life science consultancy, Back Bay Life Science Advisors, in an overview of the future of rare disease drug development and population health.
Tipping the affordability balance
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze